Arisaph Pharmaceuticals Inc Report issue

For profit Phase 2
Founded: Boston MA United States (1999)
Status: Defunct (2016)

Organization Overview

First Clinical Trial
2014
NCT02250105
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

ari-3037mo (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dyslipidemias (Phase 2)

Fatty Liver (Phase 2)

Hyperlipidemias (Phase 2)

Hypertriglyceridemia (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1